Litcius/Paper detail

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020

Sara E. Oliver, Julia W. Gargano, Mona Marin, Megan Wallace, Kathryn Curran, Mary E. Chamberland, Nancy McClung, Doug Campos‐Outcalt, Rebecca L. Morgan, Sarah Mbaeyi, José R. Romero, H. Keipp Talbot, Grace M. Lee, Beth P. Bell, Kathleen Dooling

2020MMWR Morbidity and Mortality Weekly Report334 citationsDOIOpen Access PDF

Abstract

Use of all COVID-19 vaccines authorized under an EUA, including the Moderna COVID-19 vaccine, should be implemented in conjunction with ACIP's interim recommendations for allocating initial supplies of COVID-19 vaccines (3). The ACIP recommendation for the use of the Moderna COVID-19 vaccine under EUA is interim and will be updated as additional information becomes available.

Topics & Concepts

MedicineInterimVaccinationImmunizationAdvisory committeeCoronavirus disease 2019 (COVID-19)PandemicVirologyFamily medicineInfectious disease (medical specialty)ImmunologyDiseaseInternal medicinePolitical sciencePublic administrationAntigenLawSARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyHepatitis B Virus Studies
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020 | Litcius